Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Investigational device Medicare coverage

This article was originally published in The Gray Sheet

Executive Summary

Investigational device Medicare coverage: FDA categorizes 1,031 out of 1,101 (93.6%) devices involved in ongoing investigational device exemption-approved clinical trials as "non-experimental" and thus eligible for Medicare reimbursement under a final rule published by HCFA in the Sept. 19 Federal Register ("The Gray Sheet" Sept. 18, p. 2). Under the rule, which went into effect Nov. 1, FDA is forwarding to HCFA the determinations as to whether devices used in IDE trials are "experimental" or "non-experimental." To ensure sponsors' confidentiality, FDA is releasing only IDE numbers along with a categorization decision. However, InterVentional Technologies announced Nov. 1 that its Barath surgical dilatation balloon catheter, which is involved in trials comparing restenosis rates with conventional percutaneous transluminal coronary angioplasty ("The Gray Sheet" July 18, 1994, In Brief), has been categorized as non-experimental...

You may also be interested in...



Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.

Source: 3 Former Obama US CMS Officials Being Considered To Lead Biden’s Medicare Agency

The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel